A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Alessandra Tedeschi, Richard Greil, Fatih Demirkan, Tadeusz Robak, Carol Moreno, Paul M. Barr, Bertrand Anz, David Simpson, Gianluca Gaidano, Osnat Bairey, Don Stevens, Devinder Gill, Ian W. Flinn, Thomas J. Kipps, Jan A. Burger, Jennifer Lin, Thomas Webb, Viktor Fedorov, Lori Styles, John G. Gribben

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)E164-E168
JournalHaematologica
Volume105
Issue number4
DOIs
StatePublished - Jan 1 2020

ASJC Scopus subject areas

  • Hematology

Cite this

Tedeschi, A., Greil, R., Demirkan, F., Robak, T., Moreno, C., Barr, P. M., Anz, B., Simpson, D., Gaidano, G., Bairey, O., Stevens, D., Gill, D., Flinn, I. W., Kipps, T. J., Burger, J. A., Lin, J., Webb, T., Fedorov, V., Styles, L., & Gribben, J. G. (2020). A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 105(4), E164-E168. https://doi.org/10.3324/haematol.2019.223743